Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
2021 · The Lancet Neurology · 612 citations
https://doi.org/10.1016/s1474-4422(21)00159-9